Stock Details
| Company | ACADIA Pharmaceuticals Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | USA |
| Index | - |
| P/E | - |
| EPS (ttm) | -1.20 |
| Insider Own | 0.10% |
| Shs Outstand | 160.66M |
| Perf Week | -2.60% |
| Market Cap | 3.66B |
| Forward P/E | - |
| EPS next Y | 11.80% |
| Insider Trans | -7.84% |
| Shs Float | 160.16M |
| Perf Month | -6.15% |
| Income | -191.50M |
| PEG | - |
| EPS next Q | -0.24 |
| Inst Own | 91.80% |
| Short Float | 4.13% |
| Perf Quarter | 21.09% |
| Sales | 474.40M |
| P/S | 7.72 |
| EPS this Y | -12.00% |
| Inst Trans | 0.52% |
| Short Ratio | 3.98 |
| Perf Half Y | 5.45% |
| Book/sh | 3.53 |
| P/B | 6.36 |
| ROA | -25.70% |
| Target Price | 29.05 |
| Perf Year | -58.39% |
| Cash/sh | 3.31 |
| P/C | 6.78 |
| EPS next 5Y | 25.00% |
| ROE | -32.70% |
| 52W Range | 15.68 - 54.58 |
| Perf YTD | -3.81% |
| Dividend | - |
| P/FCF | - |
| EPS past 5Y | -1.80% |
| ROI | -45.80% |
| 52W High | -58.87% |
| Beta | 0.63 |
| Dividend % | - |
| Quick Ratio | 7.10 |
| Sales past 5Y | 491.50% |
| Gross Margin | 95.40% |
| 52W Low | 43.18% |
| ATR | 1.51 |
| Employees | 570 |
| Current Ratio | 7.30 |
| Sales Q/Q | 9.10% |
| Oper. Margin | -40.70% |
| RSI (14) | 50.24 |
| Volatility | 7.18% 5.44% |
| Optionable | Yes |
| Debt/Eq | 0.00 |
| EPS Q/Q | 83.20% |
| Profit Margin | -40.40% |
| Rel Volume | 1.33 |
| Prev Close | 21.18 |
| Shortable | Yes |
| LT Debt/Eq | 0.00 |
| Earnings | Nov 08 AMC |
| Payout | - |
| Avg Volume | 1.66M |
| Price | 22.45 |
| Recom | 2.60 |
| SMA20 | -2.29% |
| SMA50 | 2.73% |
| SMA200 | 8.22% |
| Volume | 2,202,399 |
| Change | 6.00% |
Insider Trading Data
| Insider Trading | Relationship | Date | Transaction | Cost | # Shares | Value($) | # Shares Total | SEC Form 4 |
| DAVIS STEPHEN | CEO | Jan 06 | Sale | 23.05 | 3,718 | 85,700 | 58,716 | Jan 10 06:22 PM |
| Stankovic Srdjan R. | President | Jan 06 | Sale | 23.05 | 1,937 | 44,648 | 45,019 | Jan 10 06:23 PM |
| KIM AUSTIN D. | EVP & General Counsel | Jan 06 | Sale | 23.05 | 574 | 13,231 | 13,200 | Jan 10 06:24 PM |
| Teehan Brendan | EVP, COO, Head of Commercial | Jan 06 | Sale | 23.05 | 538 | 12,401 | 1,788 | Jan 10 06:25 PM |
| Stankovic Srdjan R. | President | Nov 22 | Sale | 19.01 | 2,803 | 53,285 | 41,512 | Nov 23 06:00 PM |
Latest Analyst Price Target
| date | Jan-05-22 |
| category | Upgrade |
| analyst | Citigroup |
| rating | Neutral → Buy |
| price_from | 0.0 |
| price_to | 30.0 |
Latest Stock News
- Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why
- Acadia (ACAD) Partners With Stoke for CNS Disorder Therapies
- RNA startup inks deal worth up to $967M
- Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration to Pursue Multiple RNA-based Treatments for Severe and Rare Genetic Neurodevelopmental Diseases
- Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday
Stock Details
| Company | Cincinnati Financial Corporation |
| Sector | Financial |
| Industry | Insurance - Property & Casualty |
| Country | USA |
| Index | S&P 500 |
| P/E | 7.54 |
| EPS (ttm) | 15.54 |
| Insider Own | 0.40% |
| Shs Outstand | 161.10M |
| Perf Week | -1.98% |
| Market Cap | 19.10B |
| Forward P/E | 22.68 |
| EPS next Y | -11.95% |
| Insider Trans | 0.20% |
| Shs Float | 149.16M |
| Perf Month | 4.21% |
| Income | 2.52B |
| PEG | 0.52 |
| EPS next Q | 1.43 |
| Inst Own | 69.60% |
| Short Float | 2.52% |
| Perf Quarter | -4.11% |
| Sales | 9.00B |
| P/S | 2.12 |
| EPS this Y | -38.10% |
| Inst Trans | 0.18% |
| Short Ratio | 6.87 |
| Perf Half Y | 0.34% |
| Book/sh | 73.50 |
| P/B | 1.59 |
| ROA | 8.70% |
| Target Price | 134.00 |
| Perf Year | 32.43% |
| Cash/sh | 6.66 |
| P/C | 17.60 |
| EPS next 5Y | 14.39% |
| ROE | 22.10% |
| 52W Range | 83.56 - 127.25 |
| Perf YTD | 2.84% |
| Dividend | 2.52 |
| P/FCF | 12.87 |
| EPS past 5Y | 14.40% |
| ROI | 10.90% |
| 52W High | -7.92% |
| Beta | 0.66 |
| Dividend % | 2.15% |
| Quick Ratio | - |
| Sales past 5Y | 7.90% |
| Gross Margin | - |
| 52W Low | 40.22% |
| ATR | 2.94 |
| Employees | 5266 |
| Current Ratio | - |
| Sales Q/Q | -19.80% |
| Oper. Margin | 35.50% |
| RSI (14) | 51.66 |
| Volatility | 3.03% 2.23% |
| Optionable | Yes |
| Debt/Eq | 0.08 |
| EPS Q/Q | -68.60% |
| Profit Margin | 28.10% |
| Rel Volume | 1.46 |
| Prev Close | 114.46 |
| Shortable | Yes |
| LT Debt/Eq | 0.07 |
| Earnings | Feb 15 AMC |
| Payout | 15.70% |
| Avg Volume | 548.01K |
| Price | 117.17 |
| Recom | 2.60 |
| SMA20 | 0.95% |
| SMA50 | 0.35% |
| SMA200 | -0.50% |
| Volume | 799,717 |
| Change | 2.37% |
Insider Trading Data
| Insider Trading | Relationship | Date | Transaction | Cost | # Shares | Value($) | # Shares Total | SEC Form 4 |
| Debbink Dirk J | Director | Nov 29 | Buy | 116.81 | 855 | 99,873 | 41,459 | Dec 01 03:09 PM |
| JOHNSTON STEVEN J | Chairman, President & CEO | Oct 29 | Option Exercise | 35.63 | 13,472 | 480,007 | 171,302 | Nov 02 03:04 PM |
| Brown Roger A | Sr VP, COO - Subsidiary | Aug 26 | Option Exercise | 35.63 | 1,575 | 56,117 | 23,486 | Aug 30 04:34 PM |
| Debbink Dirk J | Director | Aug 09 | Buy | 118.73 | 419 | 49,749 | 40,416 | Aug 11 02:41 PM |
| Schiff Charles Odell | Director | May 14 | Sale | 119.82 | 10,100 | 1,210,207 | 223,055 | May 18 03:51 PM |
Latest Analyst Price Target
| date | Dec-09-21 |
| category | Downgrade |
| analyst | RBC Capital Mkts |
| rating | Outperform → Sector Perform |
| price_from | 135.0 |
| price_to | 130.0 |
Latest Stock News
- Sick of rising insurance premiums? Get a cut of your own with these 3 dividend stocks
- Cincinnati Financial (CINF) Up 29% in a Year: More Upside Left?
- Cincinnati Financial Schedules Webcast to Discuss Fourth-Quarter and Full-Year 2021 Results
- Could The Cincinnati Financial Corporation (NASDAQ:CINF) Ownership Structure Tell Us Something Useful?
- 3 Dividend Kings That Should Help You Pull Through Inflation in 2022
Stock Details
| Company | Exelixis, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | USA |
| Index | - |
| P/E | 36.31 |
| EPS (ttm) | 0.51 |
| Insider Own | 0.90% |
| Shs Outstand | 315.38M |
| Perf Week | 2.21% |
| Market Cap | 5.76B |
| Forward P/E | 21.71 |
| EPS next Y | 70.26% |
| Insider Trans | -10.41% |
| Shs Float | 309.90M |
| Perf Month | -3.04% |
| Income | 164.30M |
| PEG | 0.79 |
| EPS next Q | 0.08 |
| Inst Own | 85.30% |
| Short Float | 3.80% |
| Perf Quarter | -13.46% |
| Sales | 1.25B |
| P/S | 4.59 |
| EPS this Y | -65.50% |
| Inst Trans | -0.12% |
| Short Ratio | 5.99 |
| Perf Half Y | 12.17% |
| Book/sh | 6.70 |
| P/B | 2.76 |
| ROA | 7.20% |
| Target Price | 29.62 |
| Perf Year | -18.84% |
| Cash/sh | 4.51 |
| P/C | 4.11 |
| EPS next 5Y | 46.00% |
| ROE | 8.30% |
| 52W Range | 15.50 - 25.77 |
| Perf YTD | 1.31% |
| Dividend | - |
| P/FCF | 20.95 |
| EPS past 5Y | 19.70% |
| ROI | 4.80% |
| 52W High | -28.13% |
| Beta | 0.89 |
| Dividend % | - |
| Quick Ratio | 6.10 |
| Sales past 5Y | 92.70% |
| Gross Margin | 96.10% |
| 52W Low | 19.48% |
| ATR | 0.72 |
| Employees | 773 |
| Current Ratio | 6.20 |
| Sales Q/Q | 42.10% |
| Oper. Margin | 15.50% |
| RSI (14) | 54.85 |
| Volatility | 4.80% 3.78% |
| Optionable | Yes |
| Debt/Eq | 0.00 |
| EPS Q/Q | 214.50% |
| Profit Margin | 13.10% |
| Rel Volume | 1.71 |
| Prev Close | 17.32 |
| Shortable | Yes |
| LT Debt/Eq | 0.00 |
| Earnings | Feb 17 AMC |
| Payout | 0.00% |
| Avg Volume | 1.97M |
| Price | 18.52 |
| Recom | 1.90 |
| SMA20 | 1.42% |
| SMA50 | 4.31% |
| SMA200 | -7.81% |
| Volume | 3,360,708 |
| Change | 6.93% |
Insider Trading Data
| Insider Trading | Relationship | Date | Transaction | Cost | # Shares | Value($) | # Shares Total | SEC Form 4 |
| Lamb Peter | EVP, Scientific Strategy & CSO | Dec 15 | Option Exercise | 6.21 | 47,500 | 294,975 | 410,672 | Dec 17 08:35 PM |
| Lamb Peter | EVP, Scientific Strategy & CSO | Dec 15 | Sale | 17.44 | 47,500 | 828,400 | 363,172 | Dec 17 08:35 PM |
| Haley Patrick J. | EVP, Commercial | Nov 24 | Sale | 17.25 | 17,236 | 297,321 | 237,802 | Nov 26 07:39 PM |
| FELDBAUM CARL B | Director | Nov 19 | Option Exercise | 3.13 | 20,000 | 62,600 | 28,521 | Nov 23 08:11 PM |
| FELDBAUM CARL B | Director | Nov 19 | Sale | 17.62 | 20,000 | 352,400 | 8,521 | Nov 23 08:11 PM |
Latest Analyst Price Target
| date | Nov-19-21 |
| category | Initiated |
| analyst | Piper Sandler |
| rating | Overweight |
| price_from | 0.0 |
| price_to | 34.0 |
Latest Stock News
- 5 Value Stocks That Can Make You Richer in 2022
- Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
- Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)
- Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
- Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View
Stock Details
| Company | Ionis Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | USA |
| Index | - |
| P/E | - |
| EPS (ttm) | -4.23 |
| Insider Own | 0.20% |
| Shs Outstand | 141.14M |
| Perf Week | -5.08% |
| Market Cap | 4.45B |
| Forward P/E | - |
| EPS next Y | -37.10% |
| Insider Trans | 0.00% |
| Shs Float | 140.07M |
| Perf Month | -2.88% |
| Income | -593.50M |
| PEG | - |
| EPS next Q | 0.28 |
| Inst Own | 87.10% |
| Short Float | 5.23% |
| Perf Quarter | 3.15% |
| Sales | 660.70M |
| P/S | 6.74 |
| EPS this Y | -257.00% |
| Inst Trans | 0.28% |
| Short Ratio | 6.41 |
| Perf Half Y | -16.09% |
| Book/sh | 3.76 |
| P/B | 8.35 |
| ROA | -24.90% |
| Target Price | 49.50 |
| Perf Year | -50.77% |
| Cash/sh | 14.01 |
| P/C | 2.24 |
| EPS next 5Y | - |
| ROE | -93.60% |
| 52W Range | 25.04 - 64.37 |
| Perf YTD | 3.19% |
| Dividend | - |
| P/FCF | - |
| EPS past 5Y | -34.40% |
| ROI | -29.00% |
| 52W High | -51.22% |
| Beta | 0.90 |
| Dividend % | - |
| Quick Ratio | 7.60 |
| Sales past 5Y | 20.80% |
| Gross Margin | 98.20% |
| 52W Low | 25.40% |
| ATR | 1.68 |
| Employees | 757 |
| Current Ratio | 7.70 |
| Sales Q/Q | -16.90% |
| Oper. Margin | -42.70% |
| RSI (14) | 52.06 |
| Volatility | 6.94% 5.20% |
| Optionable | Yes |
| Debt/Eq | 2.46 |
| EPS Q/Q | -233.60% |
| Profit Margin | -89.80% |
| Rel Volume | 1.42 |
| Prev Close | 29.88 |
| Shortable | Yes |
| LT Debt/Eq | 2.34 |
| Earnings | Nov 03 BMO |
| Payout | - |
| Avg Volume | 1.14M |
| Price | 31.40 |
| Recom | 2.50 |
| SMA20 | 1.18% |
| SMA50 | 2.25% |
| SMA200 | -11.59% |
| Volume | 1,625,824 |
| Change | 5.09% |
Insider Trading Data
| Insider Trading | Relationship | Date | Transaction | Cost | # Shares | Value($) | # Shares Total | SEC Form 4 |
| PARSHALL B LYNNE | Director | Jan 18 | Option Exercise | 0.00 | 5,754 | 0 | 79,132 | Jan 20 08:21 PM |
| BENNETT C FRANK | EVP, Chief Scientific Officer | Jan 18 | Option Exercise | 0.00 | 18,842 | 0 | 61,613 | Jan 20 08:21 PM |
| Cadoret-Manier Onaiza | EVP, Chf Corp Dev and Cml Offc | Jan 18 | Option Exercise | 0.00 | 6,057 | 0 | 10,687 | Jan 20 08:21 PM |
| HOUGEN ELIZABETH L | EVP, Finance & CFO | Jan 18 | Option Exercise | 0.00 | 22,050 | 0 | 65,803 | Jan 20 08:18 PM |
| O'NEIL PATRICK R. | EVP CLO & General Counsel | Jan 18 | Option Exercise | 0.00 | 21,086 | 0 | 48,094 | Jan 20 08:18 PM |
Latest Analyst Price Target
| date | Dec-14-21 |
| category | Upgrade |
| analyst | William Blair |
| rating | Mkt Perform → Outperform |
| price_from | 0.0 |
| price_to | 0.0 |
Latest Stock News
- Bard Financial Services, Inc. Buys Edison International, Ionis Pharmaceuticals Inc, Omnicom ...
- Ionis announces eplontersen receives orphan drug designation from U.S. FDA
- Mitchell & Pahl Private Wealth, Llc Buys Fair Isaac Corp, Aspen Technology Inc, Interactive ...
- Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy
- Ionis' (IONS) Partner to Begin New Huntington's Disease Study
Congratulations @librarian! You have completed the following achievement on the Hive blockchain and have been rewarded with new badge(s):
Your next target is to reach 300 upvotes.
You can view your badges on your board and compare yourself to others in the Ranking
If you no longer want to receive notifications, reply to this comment with the word
STOPCheck out the last post from @hivebuzz:
Support the HiveBuzz project. Vote for our proposal!